Luca Lanino
Milan, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).
Journal: American journal of hematology
Published: June 25, 2026
Prognostic Score for Myelodysplastic Syndromes Based on Molecular Evolution.
Journal: NEJM evidence
Published: May 26, 2026
Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 27, 2026
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.
Journal: Blood cancer journal
Published: March 13, 2026
ASSESSMENT OF THE IPSS-M IN CHRONIC MYELOMONOCYTIC LEUKEMIA.
Journal: Blood advances
Published: January 20, 2026
Myelodysplastic syndrome with concomitant SF3B1 mutation and deletion of chromosome 5 long arm: outcomes and response to treatment.
Journal: Haematologica
Published: December 18, 2025
CMML2AML: machine-learning discovery of co-mutations and specific single mutations predictive of blast transformation in chronic myelomonocytic leukemia.
Journal: Blood cancer journal
Published: November 14, 2025
Hypomethylating agents plus venetoclax versus intensive chemotherapy prior to transplant in high-risk acute myeloid leukemia.
Journal: Haematologica
Published: November 10, 2025
Longitudinal Synthetic Data Generation by Artificial Intelligence to Accelerate Clinical and Translational Research in Breast Cancer.
Journal: JCO clinical cancer informatics
Published: November 06, 2025
Last Updated: 09/26/2026